Literature DB >> 2427090

Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.

J M Kremer, J Galivan, A Streckfuss, B Kamen.   

Abstract

Serum and red blood cell methotrexate (MTX) levels, as well as hepatic levels of MTX and folate, were analyzed in 24 patients who had received long-term oral MTX weekly for the treatment of rheumatoid arthritis. The serum MTX level peaked rapidly and was insignificant after 24 hours. The red blood cell MTX level was not related to the interval from the last MTX dose. In hepatic tissue obtained by liver biopsy, MTX was found in a predominantly polyglutamated form with depleted hepatic folate stores when compared with baseline specimens. A brief period of therapy with oral folinic acid repleted hepatic folate. It is possible that MTX hepatotoxicity is related to reduced hepatic folate levels and formation of MTX polyglutamates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427090     DOI: 10.1002/art.1780290703

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  53 in total

Review 1.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

2.  Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

Authors:  M J Ahern; S Kevat; W Hill; P J Hayball; H Harley; P D Hall
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

3.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

Review 4.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

5.  Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.

Authors:  Goushi Matama; Takaaki Tokito; Hiroaki Takeoka; Yuki Hiraoka; Norikazu Matsuo; Masayuki Nakamura; Hidenobu Ishii; Takashi Kinoshita; Koichi Azuma; Kazuhiko Yamada; Tomoaki Hoshino
Journal:  Invest New Drugs       Date:  2017-03-30       Impact factor: 3.850

Review 6.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 7.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.

Authors:  J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs.

Authors:  J E Baggott; S L Morgan; T Ha; W H Vaughn; R J Hine
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

10.  Effect of folic acid on methotrexate induction of sulfotransferases in rats.

Authors:  Sangita Maiti Dutta; Smarajit Maiti; Guangping Chen
Journal:  Drug Metab Lett       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.